Comparing Delcath Systems (NASDAQ:DCTH) and TerrAscend (OTCMKTS:TSNDF)

TerrAscend (OTCMKTS:TSNDF) and Delcath Systems (NASDAQ:DCTH) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Insider & Institutional Ownership

5.8% of TerrAscend shares are held by institutional investors. Comparatively, 61.1% of Delcath Systems shares are held by institutional investors. 31.9% of TerrAscend shares are held by company insiders. Comparatively, 19.4% of Delcath Systems shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

TerrAscend has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500. Comparatively, Delcath Systems has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500.

Profitability

This table compares TerrAscend and Delcath Systems’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TerrAscend	-31.01%	-32.93%	-5.49%
Delcath Systems	0.56%	0.46%	0.42%

Valuation and Earnings

This table compares TerrAscend and Delcath Systems”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TerrAscend	$260.56 million	0.76	-$81.33 million	($0.11)	-5.82
Delcath Systems	$85.23 million	6.58	$2.70 million	$0.01	1,617.00

Delcath Systems has lower revenue, but higher earnings than TerrAscend. TerrAscend is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for TerrAscend and Delcath Systems, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TerrAscend	0	1	0	1	3.00
Delcath Systems	1	0	5	1	2.86

Delcath Systems has a consensus target price of $23.17, indicating a potential upside of 43.27%. Given Delcath Systems’ higher probable upside, analysts clearly believe Delcath Systems is more favorable than TerrAscend.

Summary

Delcath Systems beats TerrAscend on 10 of the 14 factors compared between the two stocks.

About TerrAscend

TerrAscend Corp. cultivates, processes, and sells medical and adult use cannabis in Canada and the United States. The company produces and distributes hemp-derived wellness products to retail locations; and manufactures vaporizables, concentrates, topicals, tinctures and edibles. It also operates retail dispensaries under the Apothecarium and State Flower brand names. The company was incorporated in 2017 and is headquartered in Mississauga, Canada.

About Delcath Systems

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.